Study looked at inflammatory markers in RA. The authors point to high aromatase activity, low androgens, and elevated estrone in synovial fluid as an indicator of a link between aromatase activity and inflammation production through E1 production. The authors also point to the 16 alpha metabolite pathway as pro-inflammatory as well. One very interesting point made by the authors is that vitamin D down regulates aromatase activity. In addition to NK-kappaB inhibition, this may be another mechanism by which vitamin D reduces inflammation.
aromatase inhibitor, arimidex (anastrozole), shown to be effective therapy in male infertility in those with high aromatase activity. The effect was seen through improved Testosterone:Estradiol ratio through aromatase inhibition.
ER alpha increases aromatase expression in the prostate. PGE2 increased the ER alpha receptor. Vicious cycle in men. Increased aromatase activity increases estrogen production which increases ER alpha (pro growth) and further aromatase activity.
high conversion of testosterone to estrogen conversion in men is from increased aromatase activity. Inflammatory cytokines, such as IL-6, TNF-alpha, has been shown to increase aromatase activity and at the same time increase IL-6 and other inflammatory cytokines is the result of increased aromatase activity.
aromatase activity is present in the prostate. The conversion of Testosterone to Estradiol via aromatase activity has been shown to contribute to inflammation and prostate enlargement.
red wine does appear to have health benefits over white wine through aromatase inhibition. Aromatase inhibition reduces estrogen levels. So, if the breast cancer risk is associated with elevated estrogen, then this would logically reduce the risk. The exact amount is unknown, but aromatase inhibition is a treatment of those with breast CA.
First, Testosterone pellets are not the way to go. Historically, these will go the way of all the implantable contraceptive devices. However, the conclusion of this study is good and confirms the benefit of anastrazole to inhibit aromatase activity and help to maintain Testosterone levels.
This article summarizes it all. With age, Testosterone declines and estrogen production, through elevated aromatase activity, increases. This results in a decline in the Testosterone:estradiol ratio. This has been clearly implicated in both benign and disease states of the prostate. The evidence points to aromatase activity and estrogen in the prostate to poor prostate health. Additionally, this article points out the impact of ER alpha and ER beta on the translation of the message of Estrogen.
study finds both Testosterone therapy and aromatase inhibition in men > 65 both increase Testosterone levels. Increase in prostate size was only seen in the Testosterone only group; not in the AI group. This implicates aromatase activity in the increase in prostate volume.
No surprise that Testosterone therapy improves Testosterone levels in men with low T, but aromatase inhibition (AI) did as well. In this study, only lean mass increased compared to Testosterone therapy and placebo. Strength increased in both Testosterone and AI.
inflammatory cytokine, TNF-alpha, increases aromatase activity. This article discusses the increased production of estrone from androstenedione from aromatase activity in fat tissue in the breast.
Aromatase inhibition using arimidex, anastrozole, shown to be an effective therapy to raise testosterone levels in men with low T and high aromatase activity.
Just the abstract here. Declining estradiol production found to be associated with increased cognitive dysfunction or cognitive decline in those using aromatase inhibitor therapy. Aromatase inhibition therapy is used to block Testosterone to Estradiol production in women with ER+ breast cancer.
Study looked at aromatase activity in androgen production in older men. The study found that aromatase inhibition with arimidex increased Testosterone production. PSA was also monitored and PSA increased in the smaller dose group versus the high dose group.
Study confirms aromatase activity in the prostate itself. Systemic Testosterone and Estradiol evaluation (ie blood) will not necessarily reflect endogenous prostate aromatase activity.
aromatase inhibition in men to increase Testosterone:Estradiol ratio. Men with infertility have a low Testosterone:Estradiol ratio. Aromatase inhibitors inhibit Testosterone to Estradiol conversion